Trial reportGut2005
Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis.
Trial report in Gut, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 73 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospektive, Randomisierte Doppelblinde Studie Zur Wirksamkeit Von Intestinal Retardiert Freigesetztem Phosphatidylcholine Bei therapierefraktärer Colitis Ulcerosa Mit Chronisch Aktivem Verlauf Unter Corticosteroiden
Prospektive, Randomisierte Doppelblinde Studie Zur Dosisfindung Von Intestinal Redardiert Freigesetztem Phosphatidylcholin Bei Chronisch Aktiver Pancolitis Ulcerosa
Prospektive, Randomisierte, Doppelblinde, Mesalazin-kontrollierte ("Double-dummy Verfahren) Multizenter-Studie Zur Beurteilung Der Annahme Der äquivalenten Wirkung Von Intestinal Retardiert Freigesetztem Phosphatidylcholin gegenüber Mesalazin (Non-inferiority Study) in Der Remissionserhaltung Der Colitis Ulcerosa.
Who cites it
73 citing papers in PubMed, 1 synthesis or guideline pooled it, 169 citations in OpenAlex.
- Meta-analysis of the placebo response in ulcerative colitis.Digestive diseases and sciences · 2008Pooled it
- First multicenter study of modified release phosphatidylcholine "LT-02" in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses.The American journal of gastroenterology · 2014Trial
- Safety and dose flexibility clinical evaluation of intravesical liposome in patients with interstitial cystitis or painful bladder syndrome.The Kaohsiung journal of medical sciences · 2011Trial
- Transcript levels of different cytokines and chemokines correlate with clinical and endoscopic activity in ulcerative colitis.BMC gastroenterology · 2009Trial
- Short-term duodenal seal oil administration normalised n-6 to n-3 fatty acid ratio in rectal mucosa and ameliorated bodily pain in patients with inflammatory bowel disease.Lipids in health and disease · 2006Trial
- Multi-omics Mendelian randomization and experimental validation identify PRKAB1 as a regulator of phosphatidylcholine metabolism in IBD.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Proinflammatory cytokines modify CaFrontiers in physiology · 2026Article
- Single-cell nanocapsules of gut microbiota facilitate fecal microbiota transplantation.Theranostics · 2025Article
- Underneath the Gut-Brain Axis in IBD-Evidence of the Non-Obvious.International journal of molecular sciences · 2024Review
- A mouse protozoan boosts antigen-specific mucosal IgA responses in a specific lipid metabolism- and signaling-dependent manner.Nature communications · 2024Article
- A pre-vaccination immune metabolic interplay determines the protective antibody response to a dengue virus vaccine.Cell reports · 2024Article
- Identification and validation of a blood- based diagnostic lipidomic signature of pediatric inflammatory bowel disease.Nature communications · 2024Article
- Unbiased serum metabolomic analysis in cats with naturally occurring chronic enteropathies before and after medical intervention.Scientific reports · 2024Article
- Role of myeloid cells in mediating the effects of lipids on ulcerative colitis.Frontiers in immunology · 2024Article
- Intestinal Barrier Dysfunction in Inflammatory Bowel Disease: Underpinning Pathogenesis and Therapeutics.Digestive diseases and sciences · 2023Review
- Detrimental Impacts of Pharmaceutical Excipient PEG400 on Gut Microbiota and Metabolome in Healthy Mice.Molecules (Basel, Switzerland) · 2023Article
- Plant-derived exosomal nanoparticles: potential therapeutic for inflammatory bowel disease.Nanoscale advances · 2023Review
- Cell-level systems biology model to study inflammatory bowel diseases and their treatment options.CPT: pharmacometrics & systems pharmacology · 2023Article
- The role of phosphatidylcholine 34:1 in the occurrence, development and treatment of ulcerative colitis.Acta pharmaceutica Sinica. B · 2023Article
- The Effect of Dietary Phospholipids on the Ultrastructure and Function of Intestinal Epithelial Cells.International journal of molecular sciences · 2023Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsWe examined the hypothesis of an anti-inflammatory effect of phosphatidylcholine in ulcerative colitis.
methodsA phase IIA, double blind, randomised, placebo controlled study was performed in 60 patients with chronic active, non steroid dependent, ulcerative colitis, with a clinical activity index (CAI) of > or = 4. Retarded release phosphatidylcholine rich phospholipids and placebo were administered at a dose of 6 g daily over three months. The primary end point was a change in CAI towards clinical remission (CAI < or = 3) or CAI improvement by > or = 50%. Secondary end points included > or = 50% changes in endoscopic activity index (EAI), histology, and quality of life scores.
resultsInduction of clinical remission (CAI < or = 3) as the primary outcome variable was attained by 16 (53%) patients in the phosphatidylcholine treated group compared with three (10%) in the placebo group (p<0.00001). The rate of clinical remission and CAI improvement was 90% in the phosphatidylcholine group and only 10% in the placebo group. A median drop of seven points in the CAI score (70% improvement) was recorded in the phosphatidylcholine group compared with no change in the placebo group. Secondary end point analysis revealed concomitant drops in EAI and histology scores (p = 0.00016 and p = 0.0067 compared with placebo, respectively). Improvement in quality of life was reported by 16 of 29 evaluated patients in the phosphatidylcholine group compared with two of 30 in the placebo group (p = 0.00005).
conclusionRetarded release oral phosphatidylcholine is effective in alleviating inflammatory activity caused by ulcerative colitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.